Bifogade filer
Schelin Catheter® breaking new ground again
Kurs
+8,89%
Likviditet
0,62 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2026-02-20 | 07:30 | Bokslutskommuniké 2025 |
| 2025-11-07 | 07:30 | Kvartalsrapport 2025-Q3 |
| 2025-08-21 | 07:30 | Kvartalsrapport 2025-Q2 |
| 2025-05-28 | N/A | X-dag ordinarie utdelning PLUN 0.00 SEK |
| 2025-05-27 | N/A | Årsstämma |
| 2025-05-16 | 07:30 | Kvartalsrapport 2025-Q1 |
| 2025-02-20 | - | Bokslutskommuniké 2024 |
| 2024-12-23 | - | Split PLUN 40:1 |
| 2024-12-05 | - | Extra Bolagsstämma 2024 |
| 2024-11-07 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-19 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-31 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
| 2024-05-30 | - | Årsstämma |
| 2024-05-16 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-16 | - | Bokslutskommuniké 2023 |
| 2023-11-07 | - | Kvartalsrapport 2023-Q3 |
| 2023-10-12 | - | Extra Bolagsstämma 2023 |
| 2023-07-14 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-17 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-05 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
| 2023-05-04 | - | Årsstämma |
| 2023-02-15 | - | Bokslutskommuniké 2022 |
| 2022-10-21 | - | Kvartalsrapport 2022-Q3 |
| 2022-07-14 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-06 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
| 2022-05-05 | - | Årsstämma |
| 2022-05-05 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-18 | - | Bokslutskommuniké 2021 |
| 2021-10-22 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-19 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-12 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
| 2021-05-11 | - | Årsstämma |
| 2021-05-07 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-19 | - | Bokslutskommuniké 2020 |
| 2020-10-23 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-21 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-08 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
| 2020-05-07 | - | Årsstämma |
| 2020-05-07 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-13 | - | Bokslutskommuniké 2019 |
| 2019-10-24 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-21 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-17 | - | Årsstämma |
| 2019-05-08 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
| 2019-04-16 | - | Årsstämma |
| 2019-04-16 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-22 | - | Bokslutskommuniké 2018 |
| 2018-11-14 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-21 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-17 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
| 2018-05-16 | - | Årsstämma |
| 2018-05-16 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-28 | - | Bokslutskommuniké 2017 |
| 2017-11-16 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-24 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-10 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
| 2017-05-09 | - | Årsstämma |
| 2017-05-09 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-23 | - | Bokslutskommuniké 2016 |
| 2016-11-10 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-25 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-18 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
| 2016-05-17 | - | Årsstämma |
| 2016-05-17 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-26 | - | Bokslutskommuniké 2015 |
| 2015-11-13 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-28 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-12 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
| 2015-05-11 | - | Årsstämma |
| 2015-05-11 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-27 | - | Bokslutskommuniké 2014 |
| 2014-11-28 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-29 | - | Kvartalsrapport 2014-Q2 |
| 2014-05-14 | - | Kvartalsrapport 2014-Q1 |
| 2014-05-06 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
| 2014-05-05 | - | Årsstämma |
| 2014-02-22 | - | Bokslutskommuniké 2013 |
| 2013-11-20 | - | Kvartalsrapport 2013-Q3 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Last week, Schelin Catheter® was successfully used at ASST Grande Ospedale Metropolitano Niguarda in Milan, Italy, for yet another minimally invasive method of treating benign prostatic hyperplasia (BPE). Four patients who underwent treatments with iTindTM (Registered trademark of Olympus) received intraprostatic local anesthesia through ProstaLund's injection device prior to treatments.
The Schelin Catheter® has been used for many years as standard before thermotherapy with ProstaLund's own method CoreTherm®. With the Schelin Catheter®, the prostate can be effectively anesthetized in an easy and sterile way. During the last year the device has been used in conjunction with a wide range of other prostate procedures with excellent results.
Last week, Dr Silvia Secco at ASST Grande Ospedale Metropolitano Niguarda in Milan, Italy, performed the world premiere for the Schelin Catheter in conjunction with iTindTM in four BPE-patients. The implants have been in place until today when they were removed.
Dr Silvia Secco: “I have used the Schelin Catheter in conjunction with other methods before, so I already knew the advantages to use it. But the Schelin Catheter usage made a big, big difference compared to my previous iTind cases. There were no patient complaints, and I am very impressed of the results.”
Johan Wennerholm, ProstaLund CEO: “I am extremely happy with Dr Secco´s world premiere and the results. Our fantastic device continues to exceed the high expectations from the urologists. I am really satisfied that we now have proof of concept for the Schelin Catheter in conjunction with yet another procedure.”
*iTindTM is a registered trademark owned by Olympus
For further information, please contact:
Johan Wennerholm, CEO
Tel. +46 (0) 730 429997
Email: johan.wennerholm@prostalund.com
About ProstaLund
ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company’s lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.
Certified Adviser:
Västra Hamnen Corporate Finance AB
Phone: +46 40 200 250
E-mail: ca@vhcorp.se